PDCD1 and glioblastoma: There are even Phase I clinical trials that use anti-TIM-3 and anti-PD-1 mAbs and stereotactic radiosurgery in combination for the treatment of recurrent glioblastoma multiforme to verify the effectiveness of this strategy (NCT03961971).